Cytokines are essential regulators of hematopoiesis, acting in an instructive or permissive way. Fms-like tyrosine kinase 3 ligand (FLT3L) is an important cytokine for the development of several hematopoietic populations. Its receptor (FLT3) is expressed on both myeloid and lymphoid progenitors and deletion of either the receptor or its ligand leads to defective developmental potential of hematopoietic progenitors. In vivo administration of FLT3L promotes expansion of progenitors with combined myeloid and lymphoid potential. To investigate further the role of this cytokine in hematopoietic development, we generated transgenic mice expressing high levels of human FLT3L. Transgenic mice displayed a dramatic expansion of dendritic and myeloid cells, leading to splenomegaly and blood leukocytosis. Bone marrow myeloid and lymphoid progenitors were significantly increased in numbers but retained their developmental potential. Furthermore, transgenic mice developed anemia together with a reduction in platelet numbers. FLT3L was shown to rapidly reduce the earliest erythroid progenitors when injected into wild-type mice, indicating a direct negative role of the cytokine on erythropoiesis. We conclude that FLT3L acts on multipotent progenitors in an instructive way, inducing their development into myeloid/lymphoid lineages while suppressing their megakaryocyte/erythrocyte potential.
Introduction
The development of hematopoietic cells is a highly complex and tightly regulated process that in adults is initiated in the bone marrow (BM) from hematopoietic stem cells (1) . The role of cytokines in hematopoiesis is considered to be either instructive, by directly promoting differentiation of multi-potent progenitors into a specific lineage, or permissive, by selectively promoting the survival and/or proliferation of a particular lineage at the expense of others (2) . For most hematopoietic cytokines, their precise mode of action remains unknown.
As for other type III receptor tyrosine kinases, the Fms-like tyrosine kinase 3 (FLT3), or CD135, has an extracellular domain composed of 5 immunoglobulin-like domains and a tyrosine kinase motif in the cytoplasmic domain (3) (4) (5) . These features of FLT3 are shared with other hematopoietic cytokine receptors, such as Stem Cell Factor (SCF) receptor and plateletderived growth factor (PDGF) receptor (3) . FLT3-Ligand (FLT3L) is the only known ligand for FLT3 (6) . Both the soluble and the membrane bound form of FLT3L can bind FLT3, leading to receptor dimerization and subsequent activation of the tyrosine kinase domain (7) .
Receptor activation initiates a signaling cascade involving proteins such as STAT5a, ERK1/2 and PI3K (8) .
FLT3 and its ligand have been the focus of considerable research due to their implication in leukemias, since several mutations in FLT3 have been identified in Acute Myeloid Leukemia (AML) (7) . Amongst them, the most common is an internal tandem duplication of exon 14 of the FLT3 gene (FLT3-ITD) that results in constitutive activation of the kinase domain (9) . This mutation is found in ~25% of AML and its presence constitutes a poor prognostic factor. FLT3-ITD confers growth factor-independent proliferation to leukemic cell lines and its expression in transgenic mice results in a fatal myeloproliferative syndrome (10) .
FLT3 is expressed by several hematopoietic cell populations (11) . Initially, it is expressed by non-self-renewing, short-term HSC (12, 13) . Several downstream progenitors with myeloid and/or lymphoid potential continue to express FLT3 whereas megakaryocyte/erythrocyte progenitors do not (11, (14) (15) (16) (17) (18) . With the exception of dendritic cells (DC), which retain FLT3 on their surface, FLT3 expression is down-regulated as cells undergo myeloid or lymphoid commitment. Deletion of either FLT3 or FLT3L resulted in defects in the developmental potential of myeloid/lymphoid progenitors underscoring the importance of FLT3 in their development (19, 20) . In addition, FLT3L deficient mice displayed reduced numbers of B cells, DC and Natural Killer (NK) cells (20) , while FLT3L has been shown crucial in sustaining adult B lymphopoiesis(21). However, ablation of the FLT3/FLT3L axis alone did not result in a complete block in the generation of any hematopoietic lineage, suggesting that FLT3L might exert its crucial role in hematopoiesis through interactions with other cytokines, such as Inteleukin-7 (IL-7) or SCF (19, 22, 23) .
To elucidate the specific action of FLT3L on hematopoiesis in vivo, administration of FLT3L has been carried out. Results obtained confirmed the important role of FLT3L in DC generation (24) . We have previously shown that apart from DC, FLT3L injection leads to transient expansion of a FLT3 + progenitor population with lymphoid and myeloid potential (25) . In order to evaluate the role of FLT3L on the development of different hematopoietic lineages, we describe herein the effects of sustained over-expression of FLT3L
in a transgenic mouse model. Our study confirms the positive role of FLTL in DC development and highlights the importance of this cytokine in the survival and expansion of lymphoid and myeloid progenitors. Furthermore, our data provide evidence for an instructive role of FLT3L in hematopoietic development.
Methods

Mice
All mice used herein were bred and maintained in our animal facility under pathogen free conditions and all animal experiments were performed within institutional guidelines (permission numbers 1887 and 1888). Immunizations to induce a T-dependent antibody response and FLT3L treatment of mice were carried out as previously described (25) .
Cell cultures ST2, OP9 and OP9 stromal cells expressing the Notch ligand Delta-like 1 (OP9DL1) were maintained in IMDM supplemented with 5 x 10 -5 M β -mercaptoethanol, 1mM glutamine, 0.03% w/v Primatone (Quest Naarden, The Netherlands), 100U/mL Penicillin, 100 µg/mL Streptomycin and 5% fetal bovine serum. Co-cultures of stromal cells with sorted progenitor cells were performed as previously described [(25) and Suppl. Materials and Methods].
Platelet counts
Blood was drawn from the tail vein of mice and incubated with 1% ammonium oxalate for 10 minutes at room temperature. Following incubation, live cells were counted in a Neubauer hemocytometer.
Immunofluorescence
Spleens were snap frozen and embedded in OCT-compound (Sakura, Zoetermeer, NL), and 5 µm sections were prepared. Sections were fixed in acetone for 10 min, air dried for 60 min and subsequently stained with FITC-labeled anti-CD90, PE-labeled anti-IgM and APClabeled anti-CD11c antibodies for 30 minutes.
Results
Splenomegaly and lymphadenopathy in FLT3L transgenic mice.
To investigate the effect of prolonged FLT3L over-expression, we generated mice expressing the human FLT3L gene under the control of the β-actin promoter (hereafter FLT3L-Tg mice). FLT3L levels in the blood were at the range of 500-1000 ng/ml, as assesed by ELISA using an anti-hFLT3L antibody developed in our laboratory (data not shown).
FLT3L-Tg mice were viable, fertile with no apparent signs of disease until the age of 2-3 months, when many developed diarrhea and tail necrosis. Examination of internal organs revealed a striking increase in spleen size. Indeed, total spleen cellularity in 8-14 week old FLT3L-Tg mice was 451 ± 127 x 10 6 cells compared to 71 ± 12 x 10 6 cells in wild-type (WT) littermate controls, representing a 6.3-fold increase in total cell number ( Figure 1A ). Splenic architecture was disrupted with no clearly formed T-cell follicles and a dramatic increase in Figure 1C ). The apparent increase in total BM cellularity in FLT3L-Tg mice was partly due to a marked increase in DC populations. As shown in Figure 1D Indeed, further analysis revealed these cells were CD11c + SiglecH + pDC, which had expanded 41-fold in FLT3L-Tg mice BM and were all CD127 + (Suppl. In addition, we quantified the percentages of other hematopoietic cells whose numbers were significantly altered in FLT3L-Tg mice, namely pDC and CD19 + B cell progenitors. Plasmacytoid DC seemed to increase, demonstrating a 2.6-fold increase at 5 days after FLT3L injection and reaching a 5.8-fold increase at day 7 ( Figure 5C ). This would be consistent with a role of FLT3L in expansion of these FLT3 + cells, shown previously (24, 25) .
CD19
+ CD117 + preB1 cells showed little reduction; rather an up to 2-fold increase in their percentage was observed at day 7 ( Figure 5D ). In contrast, and in accordance with our 
Analysis of FLT3L-Tg mice showed significant alterations in several hematopoietic
lineages. The population with the highest increase was DC. Both in BM and spleen, all DC populations displayed a dramatic expansion ranging from 7-to 368-fold compared to WT mice. Previously, FLT3L was shown to be a crucial factor for the in vitro generation of DC(34), whereas in vivo, absence of FLT3L resulted in a marked decrease in DC numbers (20) . Increases in DC were also noted in studies where either FLT3L was administered in vivo (24, 25) or when FLT3L was conditionally over-expressed by transgenesis (35) . The importance of FLT3L in DC generation has been shown for cDC and pDC, both of which are FLT3 + populations. Our results are in accordance with these observations. Particularly striking was the elevated numbers of pDC, the population most increased in our transgenic mice. Plasmacytoid DC are considered an important part of antiviral immunity, mainly through their production of IFN-α (36 and B cell percentages almost to WT levels (Suppl. Figure 11 ). Despite the reduction in BM P=0.0006, ***(preB2): P=0.0001, **: P=0.0014.
